Plinabulin PDE4 Inhibition for Immunotherapy Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy treatments for cancer often result in severe and life-threatening adverse events, such as autoimmune responses, which can modify drug dosage and reduce treatment effectiveness, highlighting the need for effective treatments to manage these adverse events and enhance immunotherapy safety and efficacy.
Innovation Solution
Plinabulin, a synthetic compound, is used to inhibit PDE4 activity, reducing the incidence and severity of immunotherapy-related adverse events, and when combined with immune checkpoint inhibitors, it enhances the immune response and reduces tumor size, thereby improving the safety and effectiveness of cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy is administered to treat cancer, then the immune response is enhanced and tumor size is reduced, but severe adverse events such as autoimmune responses occur
Solution Approach 1:
Plinabulin acts as an intermediary substance that modulates the immune response to cancer treatment. It selectively enhances anti-tumor immunity while suppressing harmful autoimmune reactions, thereby mediating between the therapeutic benefits and adverse effects of immunotherapy
Solution Approach 2:
The invention changes the parameter of immune response selectivity by using plinabulin to differentially regulate immune cell activity. It modifies the intensity and specificity of immune responses, enhancing tumor-targeted immunity while reducing off-target autoimmune damage
2Object-affected harmful factors
If drug dosage is modified to reduce adverse events, then safety is improved, but treatment effectiveness is reduced
Solution Approach 1:
Plinabulin serves as a protective intermediary that allows maintenance of full immunotherapy dosage by buffering against adverse effects. It enables the system to withstand higher drug doses without experiencing severe autoimmune reactions, thus preserving treatment effectiveness while ensuring safety
3Object-affected harmful factors
If plinabulin is used to reduce adverse events, then safety is improved, but the mechanism of action requires precise PDE4 inhibition
Solution Approach 1:
The invention utilizes the specific pharmacological parameter of PDE4 enzyme inhibition by plinabulin to achieve selective immune modulation. By controlling the concentration and timing of plinabulin administration, the system optimizes the inhibition of PDE4 activity in immune cells to maximize protective effects while minimizing side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Plinabulin effectively reduces the incidence and severity of immunotherapy-related adverse events, enhances the immune response, and promotes anti-tumor effects, making cancer treatment safer and more effective by targeting cancer cells and modifying the tumor microenvironment.
Implementation Method 1
Phosphodiesterases (pdes) are enzymes that hydrolyze and degrade camp. Pde4 is a camp phosphodiesterase widely expressed in hematopoietic cells... The use of plinabulin... is disclosed... plinabulin decreases chemotherapy side effects... plinabulin effectively reduces the incidence and severity of immunotherapy-related adverse events
Data Source
Figure 1
AI summary
Disclosed herein are compositions and methods of preventing and/or treating or reducing immunotherapy mediated adverse events by administering plinabulin. Some embodiments relate to treatment of immunotherapy related inflammation by administering plinabulin. Some embodiments relate to treatment of psoriasis and/or inflammation by administering plinabulin.